Does the choice of EQ-5D tariff matter? A comparison of the Swedish EQ-5D-3L index score with UK, US, Germany and Denmark among type 2 diabetes patients

Kiadaliri, Aliasghar A.; Eliasson, Björn; Gerdtham, Ulf-G

doi:10.1186/s12955-015-0344-z

Table 4 Known-group validity of the EQ-5D-3L tariffs

From: Does the choice of EQ-5D tariff matter? A comparison of the Swedish EQ-5D-3L index score with UK, US, Germany and Denmark among type 2 diabetes patients

	Sweden	UK	US	Denmark	Germany
HbA1c ≤ 7 (n = 890)	0.88	0.78	0.84	0.82	0.87
HbA1c > 7 (n = 867)	0.87	0.75	0.81	0.79	0.84
Difference	0.01*	0.04**	0.02**	0.03**	0.03**
Relative efficiency	1.00	1.29	1.25	1.37	1.25
Effect size	0.12	0.14	0.13	0.14	0.13
BMI < 30 (n = 991)	0.89	0.79	0.84	0.82	0.87
BMI ≥ 30 (n = 766)	0.86	0.74	0.80	0.78	0.83
Difference	0.03***	0.06***	0.04***	0.05***	0.04***
Relative efficiency	1.00	0.98	0.97	1.01	0.90
Effect size	0.22	0.22	0.22	0.22	0.21
Diabetes duration ≤ 8 (n = 929)	0.88	0.78	0.84	0.81	0.87
Diabetes duration > 8 (n = 828)	0.87	0.75	0.81	0.79	0.84
Difference	0.01**	0.04**	0.02**	0.03**	0.03**
Relative efficiency	1.00	1.15	1.14	1.09	1.36
Effect size	0.13	0.14	0.13	0.13	0.15
Age ≤ 67 (n = 929)	0.88	0.77	0.83	0.80	0.86
Age > 67 (n = 828)	0.87	0.76	0.82	0.80	0.85
Difference	0.01	0.01	0.01	0.01	0.01
Relative efficiency	1.00	0.41	0.81	0.41	0.84
Effect size	0.06	0.04	0.05	0.04	0.05
Microvascular complications (No) (n = 1670)	0.88	0.77	0.83	0.80	0.86
Microvascular complications (Yes) (n = 87)	0.83	0.66	0.75	0.72	0.77
Difference	0.05***	0.11***	0.08***	0.08***	0.09***
Relative efficiency	1.00	1.06	1.09	0.93	1.17
Effect size	0.42	0.43	0.44	0.40	0.45
Macrovascular complications (No) (n = 1332)	0.89	0.79	0.84	0.82	0.87
Macrovascular complications (Yes) (n = 425)	0.84	0.70	0.78	0.75	0.80
Difference	0.04***	0.08***	0.06***	0.06***	0.07***
Relative efficiency	1.00	0.76	0.78	0.69	0.85
Effect size	0.37	0.32	0.32	0.31	0.34
Myocardial infarction (No) (n = 1581)	0.88	0.77	0.83	0.81	0.86
Myocardial infarction (Yes) (n = 176)	0.85	0.71	0.79	0.76	0.81
Difference	0.03**	0.06**	0.04**	0.05**	0.05**
Relative efficiency	1.00	0.81	0.88	0.86	0.71
Effect size	0.26	0.23	0.24	0.24	0.22
Stroke (No) (n = 1643)	0.88	0.77	0.83	0.81	0.86
Stroke (Yes) (n = 114)	0.82	0.66	0.75	0.72	0.76
Difference	0.06***	0.12***	0.09***	0.09***	0.10***
Relative efficiency	1.00	0.71	0.79	0.65	0.78
Effect size	0.54	0.45	0.48	0.44	0.47
Heart failure (No) (n = 1673)	0.88	0.77	0.83	0.81	0.86
Heart failure (Yes) (n = 84)	0.82	0.65	0.74	0.71	0.75
Difference	0.06***	0.13***	0.09***	0.10***	0.11***
Relative efficiency	1.00	0.82	0.79	0.74	0.93
Effect size	0.54	0.49	0.48	0.47	0.52
Non-acute IHD (No) (n = 1533)	0.88	0.78	0.83	0.81	0.86
Non-acute IHD (Yes) (n = 224)	0.84	0.70	0.78	0.75	0.80
Difference	0.04***	0.07***	0.05***	0.06***	0.06***
Relative efficiency	1.00	0.84	0.80	0.78	0.89
Effect size	0.31	0.29	0.28	0.27	0.29
Kidney disorders (No) (n = 1710)	0.88	0.77	0.83	0.80	0.86
Kidney disorders (Yes) (n = 47)	0.82	0.61	0.72	0.69	0.73
Difference	0.06***	0.16***	0.11***	0.12	0.13***
Relative efficiency	1.00	1.28	1.33	1.13	1.43
Effect size	0.54	0.61	0.62	0.57	0.64
Retinopathy (No) (n = 1719)	0.88	0.77	0.83	0.80	0.86
Retinopathy (Yes) (n = 38)	0.84	0.69	0.77	0.74	0.80
Difference	0.04	0.08	0.06	0.06	0.06
Relative efficiency	1.00	0.85	0.98	0.79	0.82
Effect size	0.32	0.29	0.32	0.28	0.29
Insulin treatment (No) (n = 901)	0.88	0.78	0.84	0.81	0.87
Insulin treatment (Yes) (n = 856)	0.87	0.75	0.82	0.79	0.84
Difference	0.01	0.03*	0.02*	.02*	0.03**
Relative Efficiency	1.00	2.08	1.90	1.59	3.08
Effect size	0.08	0.11	0.11	0.10	0.14

*,**,*** indicates p < 0.05, p < 0.01 and p < 0.001, respectively

Back to article page

ISSN: 1477-7525

Contact us

Submission enquiries: journalsubmissions@springernature.com

Health and Quality of Life Outcomes

Contact us